These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 2208108)
21. Comparison of the effectivity of two diaminocyclohexane Pt-complexes. Balázová E; Hrubisko M; Ujházy V Neoplasma; 1985; 32(5):537-42. PubMed ID: 4069288 [TBL] [Abstract][Full Text] [Related]
22. The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation. Jennerwein MM; Eastman A; Khokhar AR Mutat Res; 1991 Jan; 254(1):89-96. PubMed ID: 1986276 [TBL] [Abstract][Full Text] [Related]
23. Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes. Khokhar AR; al-Baker S; Shamsuddin S; Siddik ZH J Med Chem; 1997 Jan; 40(1):112-6. PubMed ID: 9016335 [TBL] [Abstract][Full Text] [Related]
24. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts. Goddard P; Valenti M; Kelland LR Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451 [TBL] [Abstract][Full Text] [Related]
25. Drug resistance induction and cross-resistance studies with Pt-complexes. Hrubisko M; Balázová E; Ujházy V Neoplasma; 1984; 31(6):649-53. PubMed ID: 6542968 [TBL] [Abstract][Full Text] [Related]
26. Glutathione-mediated modulation of tetraplatin activity against sensitive and resistant tumor cells. Kido Y; Khokhar AR; Siddik ZH Biochem Pharmacol; 1994 Apr; 47(9):1635-42. PubMed ID: 8185678 [TBL] [Abstract][Full Text] [Related]
27. Antitumor activity and cross-resistance studies with Pt-ascorbato complexes. Hrubisko M; Balázová E; Kiss F; Kovácová J; Ujházy V Neoplasma; 1989; 36(6):651-7. PubMed ID: 2615869 [TBL] [Abstract][Full Text] [Related]
28. Cytotoxicity of platinum(IV) and platinum(II) complexes containing 1R,2R-cyclohexanediamine as a ligand. Yamashita T; Hirose J; Noji M; Saito R; Tomida H; Kidani Y Biol Pharm Bull; 1993 Oct; 16(10):1014-8. PubMed ID: 8287030 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice. Kido Y; Khokhar AR; Yoshida M; Thai GW; Siddik ZH Drug Metab Dispos; 1994; 22(2):312-7. PubMed ID: 8013287 [TBL] [Abstract][Full Text] [Related]
30. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Pendyala L; Kidani Y; Perez R; Wilkes J; Bernacki RJ; Creaven PJ Cancer Lett; 1995 Nov; 97(2):177-84. PubMed ID: 7497460 [TBL] [Abstract][Full Text] [Related]
31. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents. Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657 [TBL] [Abstract][Full Text] [Related]
32. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells. Micetich KC; Barnes D; Erickson LC Cancer Res; 1985 Sep; 45(9):4043-7. PubMed ID: 3896476 [TBL] [Abstract][Full Text] [Related]
33. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Luo FR; Wyrick SD; Chaney SG Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941 [TBL] [Abstract][Full Text] [Related]
34. The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. Nicolson MC; Orr RM; O'Neill CF; Harrap KR Neoplasma; 1992; 39(3):189-95. PubMed ID: 1528325 [TBL] [Abstract][Full Text] [Related]
35. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617 [TBL] [Abstract][Full Text] [Related]
36. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review). Chaney S Int J Oncol; 1995 Jun; 6(6):1291-305. PubMed ID: 21556672 [TBL] [Abstract][Full Text] [Related]
37. Preparation of antitumor oxaliplatin/cisplatin docking dinuclear platinum complex. Noji M; Kizu R; Takeda Y; Akiyama N; Yoshizaki I; Eriguchi M; Kidani Y Biomed Pharmacother; 2005 Jun; 59(5):224-9. PubMed ID: 15919175 [TBL] [Abstract][Full Text] [Related]
38. Oxaliplatin: mechanism of action and antineoplastic activity. Raymond E; Faivre S; Woynarowski JM; Chaney SG Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103 [TBL] [Abstract][Full Text] [Related]
39. Synthesis, cytotoxicity, cell uptake and DNA interstrand cross-linking of 4,4'-dipyrazolylmethane-linked multinuclear platinum anti-cancer complexes. Wheate NJ; Cullinane C; Webster LK; Collins JG Anticancer Drug Des; 2001; 16(2-3):91-8. PubMed ID: 11962517 [TBL] [Abstract][Full Text] [Related]
40. Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation. Hoeschele JD; Showalter HD; Kraker AJ; Elliott WL; Roberts BJ; Kampf JW J Med Chem; 1994 Aug; 37(17):2630-6. PubMed ID: 8064793 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]